Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.

Velikyan I, Eriksson O

Theranostics 10 (1) 437-461 [2020-01-01; online 2020-01-01]

In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.

Olof Eriksson

SciLifeLab Fellow

PubMed 31903131

DOI 10.7150/thno.38366

Crossref 10.7150/thno.38366

pmc: PMC6929622
pii: thnov10p0437

Publications 9.5.0